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Antibody-dependent enhancement of the uptake of influenza A virus by Fc receptor-bearing cells was
analyzed by using virus strains of the three human influenza A virus subtypes, A/PR/8/34 (HIN1),
A/Japan/305/57 (H2N2), and A/Port Chalmers/1/73 (H3N2). Immune sera obtained from mice following
primary infection with an HlNl, H2N2, or H3N2 subtype virus neutralized only virus of the same subtype;
however, immune sera augmented the uptake of virus across subtypes. Immune sera from HlNl-infected mice
augmented uptake of the homologous (H1N1) and H2N2 viruses. Antisera to the H2N2 virus augmented the
uptake of virus of all subtypes (HlNl, H2N2, or H3N2). Antisera to the H3N2 virus augmented the uptake of
the homologous (H3N2) and H2N2 viruses. These results show that subtype cross-reactive, nonneutralizing
antibodies augment the uptake of influenza A virus strains of different subtypes. Antibodies to neuraminidase
may contribute to the enhanced uptake of viruses of a different subtype, because N2-specific monoclonal
antibodies augmented the uptake of both A/Japan/305/57 (H2N2) and A/Port Chalmers/1/73 (H3N2) viruses.
Virus-specific antibodies have several roles in preventing
and controlling virus infections. Antibodies can inhibit viral
infection by virus neutralization. Antibodies can bind to virus-
infected cells, and infected cells can then be killed by natural
killer cells or monocytes/macrophages, which attach via Fc
receptors (FcR) to antibodies bound to infected cells; this is
referred to as antibody-dependent cell-mediated cytotoxicity.
Antibodies bound to virus-infected cells may induce comple-
ment activation, and this can result in cell lysis. In addition,
antibody bound to virus particles can enhance uptake of virus
by FcR-bearing cells, such as antigen-presenting cells (APCs).
This phenomenon, which is called antibody-dependent en-
hancement (ADE) of virus infection, has been described for
several viruses, including influenza A virus (3, 6-8, 14, 15, 17,
23).
Influenza A viruses undergo significant antigenic variation
of their hemagglutinin (HA) and neuraminidase (NA) mole-
cules, the major glycoproteins that are expressed on the viral
surface. Two types of antigenic variation occur: antigenic shift
and antigenic drift. Antigenic shift is a major antigenic change
in the HA or the NA, and three different subtypes (HlNl,
H2N2, and H3N2) of human influenza A viruses have been
detected. Antigenic drift represents less marked antigenic
changes in the HA and the NA that occur within a subtype.
We previously demonstrated by using reassortant viruses
that antibodies to the HA and NA glycoprotein spikes of
influenza virus enhance uptake of virus by FcR-bearing cells.
We also reported that cross-reactive, nonneutralizing antibod-
ies persisted and enhanced virus uptake of strains within the
H3 subtype, despite the drift of neutralizing HA epitopes (24).
Ochiai et al. also reported that cross-reactive hemagglutination
inhibition antibodies enhanced infection of influenza A virus
* Corresponding author. Mailing address: Division of Infectious
Diseases and Immunology, Department of Medicine, University of
Massachusetts Medical Center, 55 Lake Ave. North, Worcester, MA
01655. Phone: (508) 856-4182. Fax: (508) 856-5981.
strains within the Hi subtype (15). Experiments using mono-
clonal antibodies (MAbs) specific to the HA of influenza A
virus demonstrated that MAbs could be placed into three
groups based on their neutralization (N) and infection-enhanc-
ing (E) activities: group I (N+E+), group II (N+E-), and
group III (N±E+). The epitope recognized by each MAb was
identified by using escape mutant viruses which had a single
amino acid substitution compared with the parent virus (25).
The presence of ADE antibody has recently been demon-
strated by using the sera of young children after primary
infection with influenza A virus (6). In the experiments de-
scribed below, we used sera obtained from mice after primary
influenza virus infection with A/PR/8/34 (A/PR; H1N1), A/Ja-
pan/305/57 (A/Japan; H2N2), or A/Port Chalmers/1/73 (A/PC;
H3N2) and demonstrated the existence of subtype cross-
reactive antibodies that enhance uptake of virus but do not
neutralize virus of a different subtype. Furthermore, we found
that NA-specific MAbs obtained by immunizing with H2N2
subtype virus enhanced the uptake of H3N2 subtype virus
strains. The presence of cross-subtype-reactive antibodies that
enhance virus uptake into FcR-bearing cells, but do not
neutralize virus, would result in augmented cross-subtype-
reactive T- and B-cell responses.
MATERUILS AND METHODS
Viruses. Influenza A virus strains A/PR (HlNl), A/Japan
(H2N2), and A/PC (H3N2) were propagated in 9-day-old
embryonated chicken eggs. Infected allantoic fluids were har-
vested on day 3 after infection, clarified by low-speed centrif-
ugation, aliquoted, and stored at -80°C until use.
Cells. The macrophage-like P388D1 cell line (10) was ob-
tained from the American Type Culture Collection and cul-
tured in RPMI 1640 medium (Flow Laboratories, McLean,
Va.) supplemented with 10% heat-inactivated fetal calf serum,
penicillin G (100 U/ml), streptomycin (0.1 mg/ml), and 2 mM
L-glutamine. When confluent monolayers were obtained, the
cells were detached by pipetting and added at 7 x 105 cells per
3499
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chamber to an eight-chambered slide. Madin-Darby canine
kidney (MDCK) cells were maintained in Eagle's minimal
essential medium containing penicillin (100 U/ml), streptomy-
cin (0.1 mg/ml), and 2 mM L-glutamine supplemented with
10% heated-inactivated fetal calf serum and were used for
plaque neutralizing antibody titration.
Immune sera. Male BALB/c mice, purchased from Charles
River Breeding Laboratories, Inc. (Stone Ridge, N.Y.), were
infected intranasally with 100 PFU of virus under metophen
anesthesia. The mice were bled 4 weeks after infection, and the
collected sera were pooled and used as immune sera. Sera
were inactivated at 56°C for 30 min and stored -20°C.
MAbs. The methods used to obtain hybridoma cell lines
which produce antibodies to N2 neuraminidase were described
previously (26). Briefly, BALB/c mice were immunized with
one intraperitoneal injection of purified intact reassortant virus
X-7F1 (10 pg of HA protein), which possesses the hemagglu-
tinin from A/NWS/33 (HiN1) and the neuraminidase from
A/RI/5+/57 (H2N2) (9). Fusion was done by using the SP2/O
Ag 14 cell line (22) 1 to 2 months later, after a similar
intravenous booster dose of antigen. The hybridomas produc-
ing antibodies to N2 were cloned in soft agar and grown as
ascites in BALB/c mice.
ADE assay. The ADE assay was performed as described
previously (24). Briefly, P388Dl cells on eight-chambered
Lab-Tek slides were washed with phosphate-buffered saline
(PBS) after treatment with 2.5 mg of neuraminidase (Clostrid-
ium perfringens type V; Sigma) per ml. Various dilutions of the
mouse immune sera and ascites fluids were added to virus, and
the mixtures were incubated for 1 h at 37°C before infection of
the P388D, monolayers for 1 h at a multiplicity of infection of
0.001. After washing, cells were cultured in RPMI 1640
containing 10% fetal calf serum for 10 h. The cells were then
fixed and stained for the presence of influenza virus antigens by
immunofluorescence using a MAb (MAb 8251; Chemicom) to
nucleoprotein which reacts with all subtypes of influenza A
virus (2a) and fluorescein isothiocyanate-conjugated sheep
F(ab')2 fragment of anti-murine immunoglobulin G antibody.
The number of infected cells was counted in eight microscopic
fields (160X objective) in each chamber. The reproducibility of
this assay was previously demonstrated (24).
Titration of neutralizing antibody. Neutralizing antibodies
were determined in plaque assays in MDCK cells, using
six-well tissue culture plates. Serially diluted mouse immune
sera or ascites fluids were preincubated with 50 PFU of virus at
37°C for 1 h. After aspiration of medium from the well, 0.1 ml
of the mixture of virus and antibody was added to each well
and incubated at 37°C for 1 h with occasional agitation. Each
well then received 3 ml of agar medium containing minimal
essential medium, 0.1% D-glucose, 0.01% DEAE-dextran, 1%
vitamins, 0.01 mg of trypsin per ml, and 1% agar. After 2 days
of incubation in 5% CO2 at 37°C, 3 ml of 2% neutral red in
PBS was overlaid onto the agar in each well. Plaques were
counted after 10 h of incubation. The 90% plaque neutralizing
antibody titers were calculated.
ELISA. Influenza A viruses were propagated in the allantoic
fluids of embryonated chicken eggs, and concentrated virus
was prepared by centrifugation of infected allantoic fluids at
18,000 rpm in a type 19 rotor for 4 h. The pellets were
suspended in 5 ml of Hanks medium with 2% fetal calf serum.
Further purification was obtained by centrifugation for 2 h at
24,000 rpm over a 20 and 65% sucrose gradient in a Beckman
SW28 rotor. The white buffy layer between the sucrose was
collected, and viral protein content was determined by the
method of Lowry et al. (11). Purified viruses were used as
antigen for the enzyme-linked immunosorbent assay (ELISA).
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FIG. 1. Effect of dilution of murine polyclonal immune sera (anti-
A/PR, anti-A/Japan, and anti-A/PC) on A/PR (HINI) virus infection
of P388D1 cells. P388D, cells were treated with neuraminidase and
infected with A/PR virus in the absence of antibody (K) or in the
presence of various dilutions of anti-A/PR (0), anti-A/Japan (A), or
anti-A/PC (A). The number of influenza virus antigen-positive cells
was determined by indirect immunofluorescence staining 10 h after
infection. The number of infected cells is shown in parentheses.
Microtiter plates (Dynatech Laboratories, Alexandria, Va.)
were coated with purified virus (1 p,g per well) in carbonate
buffer for 24 h. After being washed with PBS-0.1% Tween 20,
the plates were blocked by a 2-h incubation with 2% bovine
serum albumin in PBS. One hundred microliters of serial
threefold dilutions of ascites fluid or serum was added for 2 h
at 37°C. After washing, 100 pl of horseradish peroxidase-
conjugated anti-murine immunoglobulin G antibody was
added for 2 h at 37°C. Plates were washed, and 100 Rl of
substrate (p-nitrophenyl phosphate) was added. The A405 was
then determined after 10 min in a Dynatech MR600 micro-
plate reader. The reciprocal of the dilution of ascites fluid at
the midpoint of the exponential part of a semilogarithmic plot
of absorbance versus the dilution of ascites fluid was taken as
the titer. Titers were expressed as the average of that dilution
in duplicate assays.
RESULTS
ADE of A/PR (HlNl) virus infection. P388D1 cells were
infected with A/PR virus alone or after mixing with mouse
polyclonal immune sera to A/PR, A/Japan, or A/PC (Fig. 1).
The number of foci of A/PR antigen-positive cells was reduced
at a serum dilution of 1:2 x 102 and was enhanced at dilutions
from 1:2 x 103 to 1:2 x 104 by homologous serum (anti-A/PR
serum). Serum from H2N2-immunized mice did not neutralize
but did enhance uptake by A/PR at a dilution of 1:2. Serum
from H3N2 virus-immune mice did not neutralize or enhance
uptake by A/PR. Plaque neutralization titers confirmed these
results (Table 1).
ADE of A/Japan (H2N2) virus infection. P388D1 cells were
infected with A/Japan virus alone or after mixing with mouse
polyclonal immune sera to A/PR, A/Japan, or A/PC (Fig. 2).
The number of foci of A/Japan antigen-positive cells was
reduced at a serum dilution of 1:2 x 102 and enhanced at
dilutions from 1:2 x 103 to 1:2 x 105 by homologous (anti-A/
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TABLE 1. Neutralization or enhancement of infectious foci of
influenza A viruses by convalescent sera
Titer of an immune serum againsta:
Virus A/PR A/Japan A/PC
N E N E N E
A/PR (H1N1) 80 2 x 104 <2 2 <2 <2
A/Japan (H2N2) <2 2 640 2 x 104 <2 20
A/PC (H3N2) <2 <2 <2 2 320 2 x 103
N, plaque neutralization; E, enhancement. Titers of antibodies to homolo-
gous virus are underlined. Titers that are above 1:1,000 are given as 10t, e.g.,
2 x104 = 1:20,000.
Japan) serum. The number of foci of A/Japan antigen-positive
cells was enhanced at dilutions of 1:2 x 10 and 1:2 x 102 by
anti-H3N2 serum and at dilutions of 1:2 and 1:2 x 10 by
anti-HlNl serum but was not reduced. Plaque neutralization
titers confirmed these results (Table 1).
ADE of A/PC (H3N2) virus infection. P388D1 cells were
infected with A/PC virus alone or after mixing with mouse
immune sera to A/PR, A/Japan, or A/PC (Fig. 3). The number
of A/PC antigen-positive foci was reduced at a serum dilution
of 1:2 x 10 and was enhanced at dilutions of 1:2 x 103 and 1:2
x 104 by the homologous (anti-A/PC) serum. The number of
A/PC antigen-positive foci was also enhanced at dilutions from
1:2 to 1:2 x 102 by anti-A/Japan serum but was not reduced.
Anti-A/PR serum neither reduced nor enhanced the number
of A/PC antigen-positive foci. Plaque neutralization titers
confirmed these results (Table 1).
Shift of neutralization or enhancement antigens on viruses
of different subtypes. Table 1 summarizes the shift of neutral-
ization or enhancement antigens of these three subtypes of
0)
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FIG. 2. Effect of dilution of murine polyclonal immune sera (anti-
A/PR, anti-A/Japan, and anti-A/PC) on A/Japan (H2N2) virus infec-
tion of P388D, cells. P388D1 cells were treated with neuraminidase
and infected with A/Japan virus in the absence of antibody (O) or in
the presence of various dilutions of anti-A/PR (0), anti-A/Japan (A),
or anti-A/PC (-). The number of influenza virus antigen-positive cells
was determined by indirect immunofluorescence staining 10 h after
infection. The number of infected cells is shown in parentheses.
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FIG. 3. Effect of dilution of murine polyclonal immune sera (anti-
A/PR, anti-A/Japan, and anti-A/PC) on A/PC (H3N2) virus infection
of P388D, cells. P388D, cells were treated with neuraminidase and
infected with A/PC virus in the absence of antibody (K) or in the
presence of various dilutions of anti-A/PR (0), anti-A/Japan (A), or
anti-A/PC (-). The number of influenza virus antigen-positive cells
was determined by indirect immunofluorescence staining 10 h after
infection. The number of infected cells is shown in parentheses.
human influenza A virus. Immune sera to each subtype virus
neutralized the homologous virus but did not neutralize virus
of other subtypes. We designated the dilution of serum at
which the greatest increase in the number of antigen-positive
foci was detected as the enhancement titer.
The enhancement titers of anti-A/PR were 2 x 104 with the
anti-A/PR homologous virus (HlNl) and 2 with the H2N2
virus; anti-A/PR did not enhance uptake by the H3N2 virus.
The enhancement titers of the anti-A/Japan serum were 2 x
104 with the homologous virus (H2N2) and 2 with the HINI
and H3N2 viruses. The enhancement titers of the anti-A/PC
serum were 2 x 103 with the homologous virus and 20 with the
H2N2 virus.
An N2 neuraminidase-specific MAb augments uptake of
virus infection by both A/Japan (H2N2) and A/PC (H3N2). We
have previously shown by using recombinant viruses that
antibodies to HA and NA enhance uptake of influenza A virus
(25). The present results demonstrate cross-reactivity of en-
hancement of virus uptake and the absence of detectable
neutralization across subtypes (Table 1). Both the A/Japan and
the A/PC viruses contain N2 NA; therefore, we analyzed
whether an NA-specific MAb could enhance the uptake by
viruses of different subtypes. Three MAbs specific to N2
neuraminidase of the X-7F1 (H1N2) virus (26) were analyzed
for the ability to reduce or enhance the number of antigen-
positive foci in P388D, cells, for plaque neutralizing activity,
and for binding of viral particles in ELISA. The N2 gene in this
H1N2 reassortant virus (X-7F1) was derived from the A/RI/
5+/57 (H2N2) virus. MAb 73/1 enhanced the number of
antigen-positive foci by the A/Japan (H2N2) virus at dilutions
from 1:10 to 1:106 (Fig. 4A). MAbs 103/1 and 415/1 also
enhanced the number of antigen-positive foci at dilutions from
1:10 to 1:104 and from 1:10 to 1:102, respectively. None of these
MAbs reduced the number of antigen-positive foci in P388D1,
cells. The A/PC (H3N2) virus strain was also analyzed with
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000 these MAbs. MAb 73/1 enhanced uptake of A/PC at dilutions
(A) from 1:10 to 1:104 but did not reduce the number of antigen-
positive foci (Fig. 4B). The other two MAbs (103/1 and 415/1)
(192) neither increased nor decreased the number of A/PC antigen-
positive foci. When MDCK cells were used in plaque neutral-
10
\ization assays, MAb 73/1 neutralized A/Japan virus at a<,100 > + dilution of 160 as reported previously (27), but A/PC virus was
B ^ \ \ not neutralized (Table 2). The other MAbs (103/1 and 415/1)
t(s1) ~ \ \ did not neutralize either A/Japan or A/PC. The ELISA titers of
73/1 against A/Japan and A/PC were 2.4 x 104 and <100,
,O | --~ ~ ~~(18) respectively. The ELISA titers of the other MAbs (103/1 and
'ri o - 415/1) against A/Japan and A/PC were <100.
U-
DISCUSSION
We previously reported that cross-reactive, nonneutralizing
antibodies persist and enhance influenza A virus uptake of
101 102 103 104 IO1 106 107 No ascites FcR-bearing cells, despite the drift of neutralizing antigens ofinfluenza A virus strains within the H3N2 subtype (24). The
Reciprocal of ascites dilution HA and NA of influenza virus A viruses induce antibodies
which augment the uptake of influenza A virus by FcR-bearing
0000 cells. This was shown by using reassortant viruses which shared
(B) only the gene for HA or NA with virus used to induce
antibodies and by using specific antisera to purified HA or NA
(24). Those results suggested that enhanced uptake could
occur between viruses of different influenza A virus subtypes as
a result of cross-reactive antibodies. In these experiments, we
demonstrate that cross-reactive, nonneutralizing antibodies
are present in immune mouse sera after primary infection and
*E
100- \that these antibodies enhance the uptake into FcR-bearing
oC \00 cells of viruses of different subtypes than that used to infect
mice. An NA-specific MAb also enhanced uptake across the
0 H2N2 and H3N2 subtypes.
U.
-31)Anti-A/PR (HlNl) serum neutralized and enhanced the
10 uptake of homologous virus and also enhanced the uptake of
the H2N2 virus at high concentrations. Anti-A/Japan serum
modestly increased the number of antigen-positive foci pro-
l lduced by A/PR, A/Japan, and A/PC viruses but reduced uptake
only by the homologous virus. Anti-A/PC serum increased the
lo1 102 103 104 10S 106 107 No ascites number of antigen-positive foci produced by A/Japan and
Reciprocal of ascites dilution A/PC uptake only by homologous
was no convincing cross-subtype-reactive neutralization ob-
FIG. 4. Effect of dilution of MAbs 73/1, 103/1, and 415/1 on the served among A/PR (HlNl), A/Japan (H2N2), and A/PC
number of foci of infected P388D1 cells by A/Japan virus (A) and A/PC (H3N2); however, cross-reactive enhancement of uptake was
virus (B). P388D1 cells were treated with neuraminidase and infected detected between the HlNl and H2N2 and the H2N2 and
with A/Japan or A/PC virus in the absence of antibody (O) or in the H3N2 subtypes. Okuno et al. recently described a MAb that
presence of various dilutions of MAb 73/1 (@), 103/1 (A), or 415/1 recognizes a conserved antigenic site on the HA of two(-). The number of influenza virus antigen-positive cells was deter- recgnies aHcNs an tinicusite Ha
mined by indirect immunofluorescence staining 10 h after infection. subtypes (HlNi and H2N2) of influenza A virus (iSa). Such
The number of infected cells is shown in parentheses. Hi and H2 cross-reactive antibodies may be contained in the
anti-A/PR and anti-A/Japan sera that we used and enhance
uptake by virus of a different subtype at high concentrations of
antibody (Fig. 1 and 2). The overall amino acid sequence
homology between the Ni and N2 proteins is 40% (5), and it
is possible that antibodies to NA also contribute to the
TABLE 2. Plaque neutralization, focus reduction or enhancement, and ELISA titers of N2 neuraminidase-specific MAbs
Titera
Virus MAb 73/1 MAb 103/1 MAb 415/1
N R E ELISA N R E ELISA N R E ELISA
A/Japan (H2N2) 160 <10 105 2.4 x 104 <10 <10 103 <100 <10 <10 10 <100
A/PC (H3N2) <10 <10 103 <100 <10 <10 <10 <100 <10 <10 <10 <100
a N, plaque neutralization; R, reduction; E, enhancement.
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INFECTION ENHANCEMENT OF INFLUENZA A VIRUSES 3503
cross-reactive enhancement of uptake of HlNl and H2N2
viruses; however, three NA-specific MAbs to N2 (73/1, 103/1,
and 415/1) neither neutralized nor enhanced the uptake of
A/PR (data not presented). Since A/Japan and A/PC viruses
share the N2 neuraminidase, we thought that neuraminidase-
specific antibodies might be contributing to this cross-subtype-
reactive increase in the number of antigen-positive foci. We
analyzed the ADE activity of three MAbs which are specific to
N2 neuraminidase. These MAbs were obtained by immunizing
mice with X-7F, (H1N2), which contains the A/RI/5+/57
neuraminidase similar to the N2 neuraminidase of A/Japan.
All of the three NA-specific MAbs enhanced uptake by the
A/Japan virus, and MAb 73/1 also enhanced uptake by the
A/PC virus. None of the three MAbs reduced the number of
antigen-positive foci by A/Japan and A/PC in P388D, cells;
however, MAb 73/1 had some neutralizing antibody on A/Ja-
pan in MDCK cells, as shown previously (26). Since P388D,
cells have FcR, virus uptake via FcR can be augmented in the
presence of antibody, and this can mask the neutralizing
activity. Thus, the effect of the ADE on uptake may contribute
to the differences observed in neutralizing activity in MDCK
cells and the number of infectious foci in P388D, cells. The
enhancement assay seems to be more sensitive than the
ELISA, because ELISA titers were lower than enhancement
titers (Table 2).
The function of NA in influenza virus infection is still
unclear; however, one function of the NA is to remove sialic
acid from the carbohydrate moiety of mucin, and this may
facilitate virus release from the infected cells (27). Generally,
polyclonal antibodies to NA do not neutralize infectivity but do
cause plaque size reduction; however, some MAbs to NA have
been reported to neutralize virus infection (26, 27). Antibody
to NA reduced the pathology or mortality caused by influenza
virus infection in mice or chickens (2, 19, 21). With emergence
of the H3 subtype in 1968 to 1969, the population had no
immunity to the H3 HA during the H3N2 epidemic but had
antibodies to the N2 because of previous infections with H2N2
viruses. Monto and Kendal reported that the frequency of
infection, which was determined serologically by hemaggluti-
nin inhibition in persons with high levels of preexisting natu-
rally acquired antibody to N2 NA, was about one-half that of
persons without antibody to N2 NA (13). They concluded that
antibody against the NA of the influenza virus prevented or
modified infection when there was no preexisting anti-H3 HA
antibody. We speculate that antibody to NA might also have
increased the number of antigen-positive APCs, thereby aug-
menting activation of influenza A virus-specific T cells. It is
interesting that MAb 73/1 neutralized only A/Japan but en-
hanced the uptake by both A/Japan and A/PC. We have
previously demonstrated that enhancing activity persisted after
neutralizing activity was lost, using several strains of virus
within H3 subtype (24). We also analyzed MAbs specific to HA
of influenza A virus and demonstrated that those MAbs could
be divided into three groups based on their N and E activities:
group I (N+E+), group II (N+E-), and group III (N±E+±).
The epitope for each MAb was identified by using escape
mutant viruses which had a single amino acid substitution
compared with the parent virus (25). MAb 73/1 recognizes
region 2 of NA molecule, which is thought to encompass most
of the top surface of the molecule (26). Further analysis will be
required to better define the epitope on NA recognized by
MAb 73/1.
FcR-bearing cells such as macrophages and B cells are APCs
for T lymphocytes (1, 18). It was reported that T-cell responses
were enhanced when FcR-bearing APCs were sensitized with
antigen in the presence of antibody (4, 12, 20). Macrophages
are not permissive for influenza A virus infection, but viral
peptides are presented to T cells on the APC surface in
association with major histocompatibility complex molecules.
Cross-reactive, nonneutralizing antibodies to HA and NA bind
to virus strains of other subtypes. This will result in an increase
in the number of antigen-positive APCs and augmented acti-
vation of influenza virus-specific T cells.
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